ProjectOASIS-2
Basic data
Title:
OASIS-2
Duration:
01/09/2018 to 31/03/2020
Abstract / short description:
Multicenter, Randomized, DoubleBlind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderateto-Severe Plaque Psoriasis (OASIS-2)
Prüfplan-Nr.: 16T-MC-AMAJ
Prüfplan-Nr.: 16T-MC-AMAJ
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Basingstoke, Hampshire, United Kingdom